• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The first Chinese oral anti-COVID-19 drug Azvudine launched.

作者信息

Yu Bin, Chang Junbiao

机构信息

College of Chemistry & School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China.

NMPA Key Laboratory for Research and Evaluation of Innovative Drug, Henan Normal University, Xinxiang 453007, China.

出版信息

Innovation (Camb). 2022 Nov 8;3(6):100321. doi: 10.1016/j.xinn.2022.100321. Epub 2022 Sep 9.

DOI:10.1016/j.xinn.2022.100321
PMID:36106026
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9461232/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f79/9513270/167a2ab145bf/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f79/9513270/167a2ab145bf/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f79/9513270/167a2ab145bf/gr1.jpg

相似文献

1
The first Chinese oral anti-COVID-19 drug Azvudine launched.首款国产口服抗新冠病毒药物阿兹夫定上市。
Innovation (Camb). 2022 Nov 8;3(6):100321. doi: 10.1016/j.xinn.2022.100321. Epub 2022 Sep 9.
2
Azvudine, a novel nucleoside reverse transcriptase inhibitor showed good drug combination features and better inhibition on drug-resistant strains than lamivudine in vitro.阿兹夫定是一种新型核苷类逆转录酶抑制剂，在体外显示出良好的药物联合特性，且对耐药菌株的抑制作用优于拉米夫定。
PLoS One. 2014 Aug 21;9(8):e105617. doi: 10.1371/journal.pone.0105617. eCollection 2014.
3
4'-Modified Nucleosides for Antiviral Drug Discovery: Achievements and Perspectives.4'-修饰核苷在抗病毒药物研发中的应用：成就与展望。
Acc Chem Res. 2022 Feb 15;55(4):565-578. doi: 10.1021/acs.accounts.1c00697. Epub 2022 Jan 25.
4
[Multi-dimensional mining and analysis of core prescriptions in launched Chinese patent medicine for treatment of influenza].[上市中成药治疗流感核心处方的多维挖掘与分析]
Zhongguo Zhong Yao Za Zhi. 2019 Nov;44(21):4738-4744. doi: 10.19540/j.cnki.cjcmm.20190812.501.
5
Analysis on oral medication rules of traditional Chinese medicine prescriptions for prevention of COVID-19.预防新型冠状病毒肺炎的中药方剂口服用药规律分析
Chin Herb Med. 2021 Oct;13(4):502-517. doi: 10.1016/j.chmed.2021.10.007. Epub 2021 Oct 12.
6
Efficacy of Traditional Chinese Medicine, Maxingshigan-Weijing in the management of COVID-19 patients with severe acute respiratory syndrome: A structured summary of a study protocol for a randomized controlled trial.中药麻杏石甘-苇茎汤治疗新型冠状病毒肺炎重型急性呼吸综合征患者的疗效：一项随机对照试验研究方案的结构化总结
Trials. 2020 Dec 23;21(1):1029. doi: 10.1186/s13063-020-04970-3.
7
The therapeutic effects of traditional chinese medicine on COVID-19: a narrative review.中医药治疗 COVID-19 的疗效：叙述性综述。
Int J Clin Pharm. 2021 Feb;43(1):35-45. doi: 10.1007/s11096-020-01153-7. Epub 2020 Sep 24.
8
The cross-sectional survey on COVID-19 vaccine hesitancy and it predictors among Chinese parents of 3-17 years aged children in Shenzhen City.深圳市 3-17 岁儿童家长对 COVID-19 疫苗犹豫及其预测因素的横断面调查。
Ann Agric Environ Med. 2022 Mar 21;29(1):120-125. doi: 10.26444/aaem/146263. Epub 2022 Feb 8.
9
[Analysis on clinical study protocols of traditional Chinese medicine for coronavirus disease 2019].[2019年冠状病毒病的中医临床研究方案分析]
Zhongguo Zhong Yao Za Zhi. 2020 Mar;45(6):1232-1241. doi: 10.19540/j.cnki.cjcmm.20200220.501.
10
[Large- scale prospective clinical study on prophylactic intervention of COVID-19 in community population using Huoxiang Zhengqi Oral Liquid and Jinhao Jiere Granules].[藿香正气口服液与金花清感颗粒对社区人群新型冠状病毒肺炎预防性干预的大规模前瞻性临床研究]
Zhongguo Zhong Yao Za Zhi. 2020 Jul;45(13):2993-3000. doi: 10.19540/j.cnki.cjcmm.20200430.501.

引用本文的文献

1
Mechanism and spectrum of inhibition of viral polymerases by 2'-deoxy-2'-β-fluoro-4'-azidocytidine or azvudine.2'-脱氧-2'-β-氟-4'-叠氮胞苷或阿兹夫定对病毒聚合酶的抑制机制及谱
NAR Mol Med. 2025 Aug 11;2(3):ugaf029. doi: 10.1093/narmme/ugaf029. eCollection 2025 Jul.
2
Effectiveness and safety of azvudine in the treatment of COVID-19 patients: a retrospective cohort study using propensity score matching.阿兹夫定治疗新冠肺炎患者的有效性和安全性：一项使用倾向评分匹配的回顾性队列研究
Front Cell Infect Microbiol. 2025 Jun 18;15:1584261. doi: 10.3389/fcimb.2025.1584261. eCollection 2025.
3
Impact of early and delayed azvudine administration on COVID-19 mortality: a retrospective study.

本文引用的文献

1
4'-Modified Nucleosides for Antiviral Drug Discovery: Achievements and Perspectives.4'-修饰核苷在抗病毒药物研发中的应用：成就与展望。
Acc Chem Res. 2022 Feb 15;55(4):565-578. doi: 10.1021/acs.accounts.1c00697. Epub 2022 Jan 25.
2
Azvudine is a thymus-homing anti-SARS-CoV-2 drug effective in treating COVID-19 patients.阿兹夫定是一种归巢至胸腺的抗新型冠状病毒药物，对治疗新冠肺炎患者有效。
Signal Transduct Target Ther. 2021 Dec 6;6(1):414. doi: 10.1038/s41392-021-00835-6.
3
Azvudine (FNC): a promising clinical candidate for COVID-19 treatment.
早期和延迟使用阿兹夫定对新型冠状病毒肺炎死亡率的影响：一项回顾性研究
Sci Rep. 2025 Jul 1;15(1):21729. doi: 10.1038/s41598-025-05381-7.
4
Real-world effectiveness and safety of oral azvudine versus Paxlovid in patients with COVID-19 and pre-existing hypertension: a multicentre, retrospective, cohort study in Henan Province, China.口服阿兹夫定与帕罗韦德治疗新型冠状病毒肺炎合并高血压患者的真实世界有效性和安全性：中国河南省一项多中心、回顾性队列研究
BMJ Open. 2025 Jun 27;15(6):e090230. doi: 10.1136/bmjopen-2024-090230.
5
Real-world data of Azvudine-induced hepatotoxicity among hospitalized COVID-19 patients in China: a retrospective case-control study.中国住院COVID-19患者中阿兹夫定引起肝毒性的真实世界数据：一项回顾性病例对照研究。
Front Pharmacol. 2025 Jun 4;16:1558054. doi: 10.3389/fphar.2025.1558054. eCollection 2025.
6
Cross-species tropism of AAV.CPP.16 in the respiratory tract and its gene therapies against pulmonary fibrosis and viral infection.腺相关病毒.CPP.16在呼吸道中的跨物种嗜性及其针对肺纤维化和病毒感染的基因治疗
Cell Rep Med. 2025 Jun 17;6(6):102144. doi: 10.1016/j.xcrm.2025.102144. Epub 2025 May 22.
7
Effectiveness of azvudine versus nirmatrelvir/ritonavir for hospitalized patients with SARS-CoV-2 infection and pre-existing liver diseases.阿兹夫定与奈玛特韦/利托那韦治疗合并基础肝病的新型冠状病毒肺炎住院患者的疗效比较
Virol J. 2025 May 19;22(1):147. doi: 10.1186/s12985-025-02771-1.
8
Advances in the effectiveness and safety of azvudine treatment: a comprehensive review.阿兹夫定治疗的有效性和安全性进展：一项全面综述。
Front Pharmacol. 2025 Apr 25;16:1524072. doi: 10.3389/fphar.2025.1524072. eCollection 2025.
9
A multicenter, real-world cohort study: effectiveness and safety of Azvudine in hospitalized COVID-19 patients with pre-existing diabetes.一项多中心、真实世界队列研究：阿兹夫定在合并糖尿病的住院COVID-19患者中的有效性和安全性。
Front Endocrinol (Lausanne). 2025 Feb 19;16:1467303. doi: 10.3389/fendo.2025.1467303. eCollection 2025.
10
Real-world efficacy and safety of azvudine in hospitalized older patients with COVID-19 during the omicron wave in China: A retrospective cohort study.阿兹夫定在中国奥密克戎毒株流行期间对住院老年 COVID-19 患者的真实世界疗效和安全性：一项回顾性队列研究。
Acta Pharm Sin B. 2025 Jan;15(1):123-132. doi: 10.1016/j.apsb.2024.12.004. Epub 2024 Dec 12.
阿兹夫定（FNC）：一种有前景的用于治疗新冠肺炎的临床候选药物。
Signal Transduct Target Ther. 2020 Oct 10;5(1):236. doi: 10.1038/s41392-020-00351-z.
4
Mechanistic Insight into Antiretroviral Potency of 2'-Deoxy-2'-β-fluoro-4'-azidocytidine (FNC) with a Long-Lasting Effect on HIV-1 Prevention.机制洞察 2'-脱氧-2'-β-氟-4'-叠氮胞苷（FNC）抗逆转录病毒效力及其对 HIV-1 预防的长效作用。
J Med Chem. 2020 Aug 13;63(15):8554-8566. doi: 10.1021/acs.jmedchem.0c00940. Epub 2020 Aug 3.